Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical stage biopharmaceutical company, is committed to developing novel monoclonal antibodies to treat cancer and hepatitis C virus (HCV) infection. The company is currently progressing three distinct clinical programs, bavituximab and Cotara® being its leading product candidates, both of which are in Phase II clinical studies for the treatment of cancer. Additionally, bavituximab is in a Phase I clinical study for the treatment of HCV infection. For further information, visit the Company’s web site at www.peregrineinc.com.